Dr. Reddy’s Laboratories Limited (NYSE:RDY) Shares Bought by Sei Investments Co.

Sei Investments Co. raised its holdings in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 399.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 82,625 shares of the company’s stock after acquiring an additional 66,072 shares during the period. Sei Investments Co.’s holdings in Dr. Reddy’s Laboratories were worth $1,305,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the business. EverSource Wealth Advisors LLC grew its position in Dr. Reddy’s Laboratories by 423.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,863 shares of the company’s stock worth $29,000 after purchasing an additional 1,507 shares during the period. POM Investment Strategies LLC boosted its stake in shares of Dr. Reddy’s Laboratories by 400.0% in the fourth quarter. POM Investment Strategies LLC now owns 2,275 shares of the company’s stock worth $36,000 after buying an additional 1,820 shares during the last quarter. Farther Finance Advisors LLC grew its holdings in Dr. Reddy’s Laboratories by 461.0% during the fourth quarter. Farther Finance Advisors LLC now owns 2,547 shares of the company’s stock worth $40,000 after acquiring an additional 2,093 shares during the period. Allworth Financial LP grew its holdings in Dr. Reddy’s Laboratories by 447.8% during the fourth quarter. Allworth Financial LP now owns 2,728 shares of the company’s stock worth $41,000 after acquiring an additional 2,230 shares during the period. Finally, Sierra Ocean LLC purchased a new position in Dr. Reddy’s Laboratories during the fourth quarter valued at approximately $43,000. 3.85% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Nomura downgraded shares of Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a report on Thursday, December 19th.

Dr. Reddy’s Laboratories Stock Performance

RDY opened at $12.37 on Monday. The firm has a market capitalization of $10.32 billion, a PE ratio of 19.69 and a beta of 0.51. The company has a current ratio of 1.92, a quick ratio of 1.38 and a debt-to-equity ratio of 0.02. Dr. Reddy’s Laboratories Limited has a twelve month low of $12.36 and a twelve month high of $16.89. The firm’s 50-day moving average price is $13.33 and its 200 day moving average price is $14.49.

Dr. Reddy’s Laboratories (NYSE:RDY) last released its quarterly earnings data on Thursday, January 23rd. The company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.19 by $0.01. Dr. Reddy’s Laboratories had a net margin of 17.25% and a return on equity of 17.87%. As a group, sell-side analysts expect that Dr. Reddy’s Laboratories Limited will post 0.8 EPS for the current fiscal year.

Dr. Reddy’s Laboratories Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.